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Introduction: Though postoperative radiation for esophageal can-
cer is offered in selected cases, there is conflicting evidence as to
whether it improves overall survival (OS). We performed a retro-
spective analysis using the Surveillance Epidemiology and End
Results database to analyze the impact of adjuvant radiation in a
large cohort of patients.
Methods: From 1998 to 2005, patients diagnosed with stage T3-
4N0M0 or T1-4N1M0 esophageal adenocarcinoma (AC) or squa-
mous cell carcinoma (SCC) who were definitively treated with
esophagectomy, with or without postoperative radiation, were se-
lected. Kaplan-Meier and Cox regression analysis were used to
compare OS and disease-specific survival (DSS).
Results: A total of 1046 patients met the selection criteria: 683
(65.3%) received surgery alone and 363 (34.7%) received postop-
erative radiation. For American Joint Committee on Cancer stage III
esophageal carcinoma (T3N1M0 or T4N0-1M0), there was signifi-
cant improvement in median and 3-year OS (p  0.001) and DSS
(p 0.001), respectively. This benefit was present for both SCC and
AC. However, for American Joint Committee on Cancer stages IIA
and IIB disease there was no significant differences in OS or DSS.
Multivariate analysis revealed that postoperative radiation was the
most significant predictor for improved OS (hazard ratio 0.70, 95%
confidence interval 0.59–0.83, p  0.001).
Conclusions: This large population-based review supports the use
of postoperative radiation for stage III SCC and AC of the esoph-
agus. Given the retrospective nature of this study, until appropriately
powered randomized trials confirm these results, caution should be
used before broadly applying these findings in clinical practice.
Key Words: Esophageal cancer, Postoperative radiation, Esopha-
gectomy, Survival, Chemotherapy.
(J Thorac Oncol. 2010;5: 244–250)
Esophageal Cancer is a relatively uncommon malignancywith 16,470 new cases estimated in 2008, accounting for
approximately 1% of all new cancer diagnoses in the United
States. However, it is quite lethal with more than 14,000
deaths.1 The treatment of choice in esophageal cancer typi-
cally involves esophagectomy for resectable tumors and con-
comitant chemoradiation for unresectable tumors. However,
the locoregional recurrence rates remain high regardless of
treatment modality. The locoregional recurrence rate has
been reported to be 30% for an radical resection and 60% for
an R1 or R2 resection.2 The locoregional recurrence has been
reported to be 50 to 55% in those treated with definitive
chemoradiation.3 In addition, 5-year survivals are poor at
approximately 25% regardless of treatment modality.2,3
Seeking a superior alternative to esophagectomy alone,
several randomized trials have recently been performed eval-
uating the role of preoperative chemoradiation.4–8 Though
the data concerning its efficacy are conflicting, use of neoad-
juvant chemoradiation has been an increasingly used treat-
ment approach.9 Phase III studies analyzing the role of
postoperative radiation have been conflicting,10–13 and phase
III trials comparing adjuvant chemotherapy to surgery alone
have revealed no overall survival (OS) benefit.14–16 There-
fore, in those for whom the primary treatment is surgery,
there is no clear indication for adjuvant treatment.
Because of the conflicting data on the role of postop-
erative radiation in esophageal cancer, we performed a ret-
rospective review using the Surveillance Epidemiology and
End Results (SEER) database to analyze whether there is a
survival benefit to adjuvant radiation in a large cohort of
patients.
MATERIALS AND METHODS
Data Source
The SEER-17 database is a National Cancer Institute
program serving as the representative cancer registry of the
United States. Data concerning individual patient demo-
graphics, diagnosis, treatment, and survival outcomes are
collected from 17 regions covering 26% of the US popula-
tion.17 Because the individual patient data are de-identified,
approval from an ethics committee or institutional review
board is not required.
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Study Cohort
From 1998 to 2005, patients diagnosed with stage
T3-4N0M0 or T1-4N1M0 esophageal adenocarcinoma (AC)
(SEER codes 8140-8389) or squamous cell carcinoma (SCC)
(SEER codes 8050-8089) who were definitively treated with
esophagectomy were selected. Before 1998 SEER did not
have a unique surgical code for esophageal cancer, and
therefore, 1998 was chosen as the earliest time period for the
cohort. Patients with T1-2N0 disease were excluded.
Patients who refused radiation therapy (RT), were coded
as unknown regarding radiation treatment or who had neoadju-
vant radiation, or any RT other than postoperative external beam
RT (postopRT), were excluded. Only patients who survived
more than 3 months postsurgery were included in the cohort.
This was done to remove possible bias in favor of the postop-
erative radiation group, because some of the patients who re-
ceived surgery alone may have died in the perioperative period
before receiving adjuvant radiation. Thus, the comparison was
strictly limited to those who were treated with definitive esoph-
agectomy with or without adjuvant radiation.
The SEER database does not include the details of
radiation delivery, such as total dose, dose distribution, tech-
nique, compliance, and overall elapsed treatment time. Sys-
temic therapy information is not available in the SEER
registry; thus, analyses based on the presence or absence of
chemotherapy were not possible.
Staging
Extent of invasion was determined using the appropriate
staging and coding manuals that correlated to patients from 1998
to 200318 and from 2004 to 2005.19 Tumor size and extent is
coded primarily from the operative report and pathology reports
and therefore likely represents pathologic staging. Extent of
nodal disease was determined based on pathologic findings only.
This information was used to convert the extent of disease to
tumor, node, metastasis staging according to the American Joint
Committee on Cancer (AJCC) staging, 6th edition.20 Table 1
lists the included patients based on their tumor, node, metastasis
classification and AJCC stage grouping.
Outcome
The primary endpoints were all-cause mortality and
esophageal cancer-specific mortality. Follow-up time was
calculated from the month and year of initial diagnosis. Vital
status at the date of last contact was available for all patients.
Statistical Analysis
Comparisons of the characteristics between the RT and
non-RT groups were made using Pearson Chi Square. Actuarial
disease-specific survival (DSS) and OS curves were generated
using the Kaplan-Meier method and compared using the log-
rank test. Separate queries were performed to analyze both DSS
and OS outcomes for all patients. DSS was defined as death
from esophageal cancer and was measured from diagnosis until
death from esophageal cancer. OS was measured from diagnosis
until death from any cause. The 3-year actuarial DSS and OS
rates, as well as median survival, were analyzed. Subgroup
analysis was also performed to analyze OS and DSS by AJCC
stage grouping as well as by histology. On univariate analysis,
the covariates analyzed included delivery of postopRT (yes
versus no), age, tumor stage (T1-2 versus T3 versus T4),
presence of pathologically positive nodes (yes versus no),
gender, race (white versus black versus other), and histologic
type (AC versus SCC). Multivariate analyses using Cox
proportional hazards survival regression analyses were per-
formed to evaluate the influence of covariates on OS. Statis-
TABLE 2. Comparison of Patient Characteristics by
Treatment Assignment
Variable All Patients (%)
PostopRT
paYes No
Age (yr) 0.095
66 499 (48) 186 (37) 313 (63)
66 547 (52) 177 (32) 370 (68)
Histologic type 0.393
AC 688 (66) 245 (36) 443 (64)
SCC 358 (34) 118 (33) 240 (67)
Gender 0.006
Female 232 (22) 63 (27) 169 (73)
Male 814 (78) 300 (37) 514 (63)
Stage 0.001
IIA 259 (25) 69 (27) 190 (73)
IIB 207 (20) 63 (30) 147 (70)
III 571 (55) 231 (40) 346 (60)
T classification 0.208
T1–2 210 (20) 63 (30) 147 (70)
T3 697 (67) 254 (36) 443 (64)
T4 139 (13) 46 (33) 93 (67)
LN status 0.005
Negative 302 (29) 85 (28) 217 (72)
Positive 744 (71) 278 (37) 466 (63)
Race 0.682
White 906 (87) 310 (34) 596 (66)
Black 81 (8) 30 (37) 51 (63)
Other 59 (5) 23 (39) 36 (61)
Data presented as number of patients, with percentages in parentheses, unless
otherwise noted.
a 2 p value.
postopRT, postoperative radiation therapy; AC, adenocarcinoma; SCC, squamous
cell carcinoma; LN, lymph node.
TABLE 1. Patient Characteristics Based on TNM
Classification and AJCC Stage Grouping
Stage
Grouping PostopRT
Surgery
Alone
Total No. of
Patients
T3N0 IIA 69 190 259
T1N1 IIB 26 73 99
T2N1 IIB 37 74 111
T3N1 III 185 253 438
T4N0 III 16 27 43
T4N1 III 30 66 96
Total no. of patients 363 683 1046
TNM, tumor, node, metastases based classification; AJCC, American Joint Com-
mittee on Cancer; postopRT, postoperative radiation therapy.
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tical analysis was performed using SPSS version 16.0 (SPSS
Inc., Chicago Illinois). Statistical significance was defined as
a two-sided p value of 0.05 or less.
RESULTS
A total of 1046 patients met the selection criteria: 683
(65.3%) received surgery alone and 363 (34.7%) received post-
operative radiation. The median age of all patients was 66 years.
The median number of nodes removed was 11. Table 2 lists
available patient characteristics and the comparisons for the
characteristics by treatment assignment. Patients who received
postopRT were more often male and had node positive disease.
OS and DSS
The use of postopRT was associated with significantly
improved OS (p  0.010) and DSS (p  0.042). The median
OS was 24 months in the group receiving postopRT and 18
months in the group undergoing surgery alone. The addition
of postopRT improved OS at 3 years from 31.2 to 34.5%
compared with surgery alone. DSS was improved at3 years
from 40.5 to 44%. The median DSS was 28 months in the
group receiving postopRT and 25 months in the group un-
dergoing surgery alone. On subgroup analysis, the OS and
DSS benefit of postopRT was noted to be significant only for
AJCC stage III disease and not for AJCC stages IIA and IIB.
Survival by AJCC Stage Grouping
For AJCC stage IIA (T3N0), 190 patients underwent
surgery alone and 69 patients received postopRT. There was
no significant OS benefit with the use of postopRT. The
median and 3-year OS were 27 months and 46.4% in the
surgery alone group compared with 46 months and 51.9% in
the postopRT group, respectively (p  0.245). Similarly,
there was no significant difference in DSS between surgery
alone and postopRT (p  0.344).
For AJCC stage IIB (T1N1 or T2N1), 147 patients
underwent surgery alone and 63 patients received postopRT.
Again, there was no significant OS benefit with the use of
postopRT. The median and 3-year OS were 25 months and
41.5% in the surgery alone group compared with 30 months
and 42.1% in the postopRT group, respectively (p  0.449).
There was also no significant difference in DSS between
surgery alone and postopRT (p  0.588).
For AJCC stage III (T3N1 or T4N0-1), 346 patients
underwent surgery alone and 231 patients received
postopRT. Use of postopRT resulted in an improvement in
median OS from 15 months to 19 months and an improve-
ment in 3-year OS from 18.2 to 28.9% (p  0.001) (Figure
1). Similarly, use of postopRT improved the median DSS
from 18 months to 24 months and improved 3-year DSS
from 27 to 38.1% (p  0.001).
Survival by Histology
Squamous Cell Carcinoma
A total of 240 patients with SCC received surgery alone
compared with 118 patients who received postopRT. Median
OS was improved from 17 months to 24 months with the
FIGURE 1. Kaplan-Meier estimates for overall
survival for patients receiving postopRT com-
pared with surgery alone for AJCC stage III.
The median survival was 19 months for
postopRT versus 15 months for surgery alone
(p  0.001). postopRT, postoperative radiation
therapy.
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addition of postopRT as well as an improvement in 3-year OS
from 28.4 to 35.7% (p  0.049). When these patients were
grouped by AJCC stage, there was no OS benefit for stage
IIA or IIB disease (p  0.259 and p  0.846, respectively).
For stage III SCC, 114 patients received surgery alone and 79
patients received postopRT. Median OS improved from 12
months to 18 months, and 3-year OS improved from 21.7 to
33.4% (p  0.011) (Figure 2). Similarly, when analyzing
DSS, there was no significant differences for stage IIA or IIB
disease (p  0.751 and p  0.898, respectively). However,
for stage III disease, median DSS improved from 17 months
to 27 months, and 3-year DSS improved from 29.6 to 44.7%
(p  0.019).
Adenocarcinoma
A total of 443 patients with AC received surgery alone
and 245 patients received postopRT. The median OS and
3-year OS were 25 months and 33.8% for those who received
postopRT compared with 19 months and 32.3% for those
who received surgery alone (p  0.086). When these patients
were grouped by AJCC stage, there was no OS benefit for
stage IIA or IIB disease (p  0.632 and p  0.517, respec-
tively). For stage III, 152 patients received postopRT and 232
received surgery alone. The median OS improved from 15
months to 20 months, and the 3-year OS improved from 16.5
to 26.3% with the addition of postopRT (p  0.002) (Figure
3). Similarly, when analyzing DSS, there was no significant
differences for stage IIA or IIB disease (p  0.371 and p 
0.531, respectively). However, for stage III disease, median
DSS improved from 19 months to 24 months, and 3-year DSS
improved from 25.7 to 34.8% (p  0.010).
Univariate and Multivariate Analyses
On univariate analysis, postopRT (hazard ratio [HR]
0.81, 95% confidence interval [CI] 0.69–0.95, p  0.011)
was associated with improved survival. Higher T stage,
positive lymph nodes, and black race were all associated with
decreased OS (Table 3).
On multivariate analysis, use of postopRT was again
associated with improved survival (HR 0.70, 95% CI 0.59–
0.83, p  0.001), as was female gender (HR 0.78, 95% CI
0.63–0.95, p 0.013). Positive lymph nodes and higher T stage
were again associated with decreased survival (Table 4).
DISCUSSION
The results of this large population-based study reveal
that the addition of postopRT is associated with significantly
improved OS and DSS for AJCC stage III esophageal cancer.
Use of postopRT significantly improved median OS by 4
months (p  0.001) and the median DSS by 6 months (p 
0.001). When stratifying by stage and by histology the sur-
vival benefit associated with postopRT remains for stage III
SCC and AC.
Because of the previously mentioned high rate of lo-
coregional recurrence after surgery alone, several institutions
treated these patients adjuvantly with radiation, reporting an
FIGURE 2. Kaplan-Meier estimates for overall
survival for patients receiving postopRT com-
pared with surgery alone for AJCC stage III
squamous cell carcinoma. The median survival
was 18 months for postopRT versus 12 months
for surgery alone (p  0.011). AJCC, American
Joint Committee on Cancer; postopRT, postop-
erative radiation therapy.
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FIGURE 3. Kaplan-Meier estimates for overall
survival for patients receiving postopRT com-
pared with surgery alone for AJCC stage III ad-
enocarcinoma. The median survival was 20
months for postopRT versus 15 months for sur-
gery alone (p  0.002). AJCC, American Joint
Committee on Cancer; postopRT, postopera-
tive radiation therapy.
TABLE 3. Univariate Analysis for Survival
Variable CHR 95% CI p
Age (continuous) 1.00 0.99–1.01 0.687
Gender
Female 0.85 0.71–1.03 0.092
Male 1
Postoperative radiation
Yes 0.81 0.69–0.95 0.011
No 1
Histology
Squamous cell carcinoma 1
Adenocarcinoma 0.91 0.77–1.06 0.233
T-stage
T1–2 1
T3 1.32 1.07–1.63 0.008
T4 1.69 1.29–2.21 0.001
Positive lymph nodes
Yes 1.60 1.33–1.92 0.001
No 1
Race
Black 1.38 1.05–1.81 0.022
Other 0.86 0.61–1.21 0.379
White 1
95% CI, 95% Confidence Interval; CHR, Cox hazard ratio.
TABLE 4. Multivariate Analysis for Survival
Variable CHR 95% CI p
Age (continuous) 1.00 0.99–1.01 0.591
Gender
Female 0.78 0.63–0.95 0.013
Male 1
Postoperative radiation
Yes 0.70 0.59–0.83 0.001
No 1
Histology
Adenocarcinoma 1
Squamous cell carcinoma 1.17 0.96–1.41 0.116
T-stage
T1–2 1
T3 1.73 1.40–2.15 0.001
T4 2.11 1.60–2.77 0.001
Positive lymph nodes
Yes 1.94 1.59–2.35 0.001
No 1
Race
Black 1.34 0.99–1.81 0.055
Other 0.87 0.61–0.95 0.43
White 1
95% CI, 95% Confidence Interval; CHR, Cox hazard ratio.
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improvement in local control.21,22 In an attempt to further
clarify the impact of postopRT in a prospective fashion,
several randomized studies were performed comparing
postopRT with surgery alone. However, the majority of the
evidence has revealed that postopRT does not confer any
survival benefit over surgery alone.
Te´nie`re et al.10 evaluated 221 patients with epidermoid
carcinoma of the middle to lower third of the esophagus who
were randomized to postopRT to a dose of 45–55 Gy versus
observation. They found that although local control improved
from 15 to 30%, there was no survival benefit with the
addition of postopRT. Fok et al.11 also randomized 130
patients with esophageal carcinoma (SCC or AC) to obser-
vation versus postopRT to a dose of 49.5 Gy in 3.5 Gy
fractions. They found that although local failure was reduced
from 31 to 15% (p 0.06), median OS was actually worse in
the postopRT arm (8.7 months versus 15.2 months, p 
0.02). This trial has been criticized, however, for the high-
dose per fraction that may have led to increased mortality in
the radiation containing arm. Zieren et al.12 randomized 68
patients with SCC to either postopRT or surgery alone and
found that postopRT significantly increased the fibrotic stric-
ture rate and did not improve OS or disease free survival.
Malthaner et al.23 performed a meta-analysis of 995 patients
from five randomized trials of postopRT versus observation.
They found that there was no OS benefit with the addition of
postopRT, with a risk ratio for death at 1 year of 1.23 (95%
CI 0.95–1.59, p 0.11). Therefore, it has been suggested that
there are little data to suggest that postopRT affords any
survival benefit.24
However, all of the aforementioned trials did not strat-
ify the patients based on their stage and likely were not large
enough to detect an improvement in survival only for those
patients with stage III disease. In addition, both Te´nie`re
et al.10 and Zieren et al.,12 included patients with positive
celiac nodes (stage M1a). These patients are excluded from
our study and represent a cohort at much higher risk for
distant failure and therefore are less likely to benefit from
postopRT. Finally, the meta-analysis included the above
flawed trials, but also did not analyze outcome of these patients
based on their stage grouping which may obscure the potential
benefit of postopRT in patients with stage III disease.
Adding credence to this argument is the results of the
largest trial presented in the meta-analysis, which found a
survival benefit only for those with stage III disease. Xiao et
al.13 randomized 495 patients with esophageal SCC to radical
resection alone versus postopRT to a total dose of 50–60 Gy
in 2 Gy fractions. Once again, there was no survival benefit
for the entire cohort with the addition of postopRT, with a
5-year OS of 31.7% for surgery alone versus 41.3% for
postopRT (p  0.4474). However, when stratifying based on
stage, there was a significant survival benefit with postopRT
for stage III patients, with an improvement in 5-year OS from
13.1 to 35.1%, (p  0.0027) but not for stage II patients.
However, this trial has been criticized for not adhering to
intent-to-treat principles. They excluded 54 patients in the
postopRT arm from their analysis who did not complete the
treatment as prescribed. In addition, informed consent was not
obtained prior to enrolling in this study. These questions have
led to significant concerns regarding the validity of these data.24
Similar to the findings by Xiao et al., our study revealed
that postopRT significantly improved OS for patients with
stage III disease only. Additionally, although Xiao et al. only
evaluated patients with squamous cell carcinoma, we found
in our study that postopRT is beneficial for both stage III SCC
and AC. The benefit of adjuvant radiation for esophageal AC
has not been previously reported in the literature.
The National Comprehensive Cancer Network (NCCN)
does recommend postoperative chemoradiation for stages
II–III esophageal AC.25 This recommendation is based on a
randomized phase III trial by Macdonald et al.26 that found
that postoperative chemoradiation improved 3-year OS from
41 to 50% in ACs of the stomach and gastroesophageal
junction. However, this trial is criticized because 54% of
patients had a suboptimal lymph node dissection, and there-
fore, it is not clear whether the adjuvant treatment compen-
sated for inadequate surgery. Furthermore, although the
NCCN uses this trial as the basis for recommending adjuvant
treatment, tumors of the thoracic esophagus were not in-
cluded in this study.
There are several limitations of this study that require
comment. One limitation is the lack of chemotherapy data from
the SEER database. Adjuvant chemotherapy has been evaluated
in three randomized trials, as well as one meta-analysis, and
have not revealed an OS benefit.14–16,27 Therefore, it is unclear
whether the inclusion of these data would alter the significance
of our findings. Neoadjuvant chemotherapy has been evaluated
in multiple randomized trials, as well as two meta-analyses, with
conflicting results. Thirion et al.28 recently performed a meta-
analysis on nine randomized trials and 2102 patients. They
found an absolute survival benefit of 4% with the addition of
neoadjuvant chemotherapy. Gebski et al.29 reported a meta-
analysis on eight randomized trials and 1724 patients and found
an absolute survival benefit of 7%, but only in those with ACs.
There was no benefit in those with squamous cell carcinomas.
However, these studies did not include patients who received
postopRT, and it is unclear how neoadjuvant chemotherapy
would have affected the outcome in these patients. Nevertheless,
without having access to the chemotherapy data, we cannot say
for certain that it had no impact on the outcome reported here,
and therefore does remain a limitation and potential source of
bias in this study.
Other limitations include the lack of information regard-
ing performance status of the patients, margin status, radiation
dose, and radiation fields that were used. In an attempt to
account for bias in selecting treatment based on performance
status, we excluded all patients who survived 3 months or less
after surgery was completed. Therefore, patients with poor
performance status, who were more likely to die during the
perioperative period, were likely excluded from this analysis.
Margin status is also likely to be an important negative
prognostic factor and is missing from this database. However,
traditionally, it is these patients that would be more likely to
have been referred for postopRT, causing a bias toward worse
outcome in the patients receiving radiation compared with
those undergoing surgery alone. In addition, on univariate
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and multivariate analysis, having positive lymph nodes was
significantly associated with worse outcome (Tables 3, 4).
However, it was those patients with positive lymph nodes
who were significantly more likely to receive postopRT
(Table 2), likely providing a further bias against improved
survival in the postopRT patients. Despite these negative
prognostic factors, postopRT is associated with a survival
benefit for stage III disease.
The NCCN recommends upfront surgery only for select
patients with clinical T1 disease. For all other stages, chemo-
radiation, preoperative chemoradiation, or preoperative che-
motherapy is recommended.25 Although our results do sup-
port the use for postopRT in stage III esophageal cancer, we
do not feel that this data provides evidence that primary
surgery followed by postopRT should replace the current
NCCN recommendations for treatment of this disease.
In conclusion, for those who do undergo primary sur-
gery, the results of this retrospective population-based anal-
ysis reveals that there is an association of improved OS and
DSS with postopRT for stage III esophageal AC and squa-
mous cell carcinoma. No significant differences were noted
for stage IIA or IIB disease, though given the retrospective
nature of this analysis, these results may have been under-
powered to detect this difference. Given the retrospective
nature of this study, until appropriately powered randomized
trials confirm these results, caution should be used before
broadly applying these findings in clinical practice.
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